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ABSTRACT
Radiation therapy (RT) is one of the primary treatment modalities for head and neck
squamous cell carcinoma (HNSCC). At the time of diagnosis two-thirds of HNSCC
patients have local-advanced disease and 50-60% of these patients will experience a
local-regional or metastatic relapse within three years. Improving the immunogenic
response of RT may help address this clinical problem. However, current RT regimens
have failed to reliably generate robust antitumor immunity as evidenced by the rarity of
clinical abscopal responses. Recently we engineered a chimeric fusion molecule called
Flagrp170, a novel immunostimulatory agent highly capable of promoting antigen
presentation and T-cell activation. We hypothesize that the combination of RT and
Flagrp170 provides superior immunogenic signals producing effective and durable
antitumor immunity against HNSCC. We report that administration of Flagrp170 to the
tumor sites upon RT using a small animal radiation research platform (SARPP) results
in potent activation of antigen-presenting cells, increased functionality of tumorinfiltrating T-cells, and systemic immune augmentation. Additionally, the combination
treatment is able to reduce the dose of RT required for tumor control and protects
previously cured animals from subsequent tumor re-challenge. Finally, the combination
treatment can successfully control the contralateral untreated tumors, supporting the
superior activity of Flagrp170 in potentiating abscopal responses of RT. Our data
suggest that the Flagrp170 may be used to enhance immunogenic cancer cell death in
RT and resultant protective antitumor immunity can potentially help reduce post-RT
recurrence of HNSCC.
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INTRODUCTION
A Historic Review and Rationale for Heat Shock Protein Cancer Vaccines
Heat shock proteins (Hsp) are a set of highly conserved molecules common to all
kingdoms of life. The heat shock response that is associated with induction of Hsp was
first discovered unexpectedly in 1962 by Ferruccio Ritossa when cells derived from
Drosophila salivary glands were accidentally exposed to hyperthermic conditions (1). A
striking pattern of polytene chromosome puffs were described in these cells and later
identified as the transcription sites of the common “heat shock response” genes (2).
Based on their molecular sizes, mammalian Hsp are categorized into several major
families, including small Hsp (e. g., Hsp27), the Hsp40, the Hsp60, the Hsp70, the
Hsp90, and the large Hsp (e.g., Hsp110, glucose-regulated protein 170 or Grp170). In
addition to hyperthermia, Hsp expression can be induced by a broad range of cellular
stressors including oncogenic stress, the accumulation of unfolded proteins, hypoxia,
oxidative stress, and the genotoxic stress caused by ionizing radiation or
chemotherapeutic drugs (3, 4).

Hsp are constitutively expressed at basal levels and primarily function as
intracellular chaperones in the folding, assembly, transportation, and degradation of
misfolded proteins. These functions are necessary for the recovery of protein
homeostasis in response to cellular stressors (5). However, extensive studies over the
past twenty years indicate that, upon release into the extracellular environment, Hsp
can assume an immunostimulatory role by facilitating the delivery of multiple
intracellular antigens, sometimes referred to as an ‘antigenic fingerprint’ to specialized
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antigen-presenting cells (APCs). Hsp can also act as damage-associated molecular
patterns (DAMPs) to promote immune activation. This interaction between extracellular
Hsp and the immune system is believed to represent an endogenous and ancient form
of immune surveillance (6, 7). This also provides an immunological basis for utilizing
cancer cell-derived or reconstituted Hsp-antigen complexes to elicit potent antitumor
immunity for cancer immunotherapy (8, 9).
The ‘abscopal effect’ is a rare immune phenomenon wherein an adaptive
antitumor immune response generated by radiation therapy (RT) results in the inhibition
of metastases outside of the field of radiation (10). In the past two decades, an evergrowing body of evidence suggests that RT also has potent local immunomodulatory
effects (11-17). As these effects have become more appreciated, the clinical potential of
combining RT and immunotherapy to immunologically sensitizing irradiated tumors to
RT has become an active area of research (18-25). Next-generation immunotherapies
such as Hsp vaccines and immune checkpoint blockade (ICB) may be strategically
developed to amplify RT-associated ‘abscopal’ effect and to generate systemic
antitumor immunity capable of controlling metastatic diseases. In this thesis, we will
discuss the current understanding of the immunostimulatory features of Hsp, their
preclinical and clinical utilizations to date, as well as their potential for modulation of
tumor microenvironment which can be exploited to synergize with RT to achieve lasting
clinical effects in the treatment of head and neck squamous cell carcinomas (HNSCC).
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Historical Tumor-derived Hsp for Cancer Vaccination
Different subcellular compartments have their own dedicated species of Hsp. Under
physiological conditions, Hsp70, Hsp90 and Hsp110 are localized in the nucleus or
cytosol, while their corresponding homologues Grp78, Grp94 and Grp170 are
endoplasmic reticulum (ER) residents (2). While Grp are functionally and structurally
related to Hsp, they are induced by different sets of stressors including chronic hypoxia,
calcium ionophores, and inhibition of glycosylation (26, 27). The nomenclatures of Hsp
and Grp were derived from their original discoveries. However, these two terms have
been used interchangeably in some cases due to the fact that both are essential integral
components of cellular stress responsive network. Intracellular Hsp and Grp play a
cytoprotective role in normal and cancerous cells by interacting with their client proteins,
minimizing stress-induced protein denaturation, and promoting cell survival. As a result,
Hsp overexpression has been shown to facilitate tumor development and to positively
correlate with poor prognosis in multiple cancers such as ovarian, prostate, breast, and
colorectal cancer (7, 28-30).
The key chaperoning function of Hsp is facilitating the correct folding of nascent
or misfolded proteins via the binding of hydrophobic regions exposed to the cytosol.
This function also prevents the aggregation of misfolded proteins in cancer cells which
may otherwise accumulate as a result of oncogenic stress, leading to apoptosis. This is
also believed to represent a major mechanism by which Hsp overexpression confers
tumor resistance to chemotherapy or RT (31-33) Additionally, other cytoprotective
activities of Hsp have also been elucidated. For instance, Hsp were shown to bind and
neutralize chemotherapeutic agents, free radicals, and cytotoxic cytokines such as
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tumor necrosis factor (TNF)α/β (34-37). Given that Hsp often interact with several
oncogenic drivers of tumorigenesis and that Hsp protect cancer cells from the cytotoxic
effects of cancer therapeutics, a large number of small molecule inhibitors of Hsp are
being tested as potential therapeutic agents (38).
Despite the well documented tumor-promoting properties of Hsp, other
investigations demonstrate that tumor-derived Hsp carry an array of antigenic tumorassociated peptides and can be utilized to generate potent antitumor responses with
lasting immunological memory against cancers (39-43). In addition to the conventional
Hsp prepared from cancer cell lines, treatment with large Hsp such as Hsp110 and
Grp170 derived from autologous tumors (e.g., methylcholanthrene-induced
fibrosarcoma, colon carcinoma, and melanoma) also elicit a robust T-cell-mediated
antitumor immunity (44, 45). This immunotherapeutic effect has been attributed to the
ability of Hsp to efficiently chaperone tumor-associated antigens (TAAs) and to enhance
the cross-priming of antigen-specific T lymphocytes (46-48)

Reconstitution of Hsp-TAA Complexes for Cancer Immunotherapy
While autologous Hsp vaccines carry an immunological “fingerprint” of the patient’s
tumor and represent a personalized medicine, its clinical use is often limited by the
needs for excised patient specimen and the complex ex vivo procedure of vaccine
preparation. The lack of antigenic information on targeted TAAs also reduces immune
monitoring capability in the clinic (49-51). To circumvent these limitations, we developed
a chaperoning technology to reconstitute Hsp-TAA complexes by taking advantage of
the superior protein or polypeptide-holding capacity of the large Hsp (i.e., Hsp110,
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Grp170) (45, 52-56). The clinically relevant TAAs that have been tested using this
recombinant chaperone vaccine include melanoma antigen glycoprotein 100 (gp100),
breast cancer antigen human epidermal growth factor receptor 2 protein (i.e.,
HER2/Neu), and renal cell carcinoma antigen carbonic anhydrase IX. In one study,
immunization with Hsp110 coupled to human HER2/neu antigen successfully
suppressed the development of murine spontaneous breast cancer (53).
This recombinant approach has the advantages of not requiring patient specimen
as well as easy bulk preparation of the “off-the-shelf” products for clinical applications.
This vaccine can be used in an adjuvant setting to treat patients with completely
resected disease, or those at a high risk for recurrence. However, the antigenic
repertoire from the targeted TAAs may not be sufficient for eradicating heterogeneous
cancer cells in solid tumors, and tumors may become resistant to single-valent
vaccination by simply downregulating the target antigen. Nonetheless, this synthetic
approach can serve as a building block to formulate recombinant chaperone vaccines
concurrently targeting multiple TAAs to augment multivalent T-cell responses, which
can help minimize cancer escape. Using the B16 melanoma model, our lab
demonstrated that the combination of melanoma antigens tyrosinase-related protein 2
and gp100 complexed with Grp170 or Hsp110 provided better antitumor protection as
compared to either of the single antigen-targeted vaccine (57).
TAAs (e.g., HER2/Neu) are antigens that are often highly expressed by tumors
and are not strictly unique epitopes to tumor tissues. Another group of tumor antigens
are those genes whose expression is normally restricted to a particular tissue or period
of embryonic development. Inappropriate acquisition of expression of these genes may
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impart a degree of “stemness” to cancer cells, making them more capable of rapid
division, invasion, and avoiding apoptosis. These antigens are collectively referred to as
cancer testis antigens (CTAs), which include MAGE-1, NY-ESO-1, SSX, and CAGE
(58). However, TAAs including CTAs are also expressed in normal tissues and
autoimmune complications from immunotherapy can occur. One recent example of a
severe adverse event occurred in a clinical trial of chimeric antigen receptor-T-cell
therapy targeting the MAGE-3. Two out of nine patients that received this treatment
developed periventricular necrotizing leukoencephalopathy and subsequently lapsed
into comas and died. This study suggests that the immunotoxicity was likely due to the
unforeseen expression of the targeted isoform in the brain (59). Although reports of
Hsp-reactive autoantibodies have been detected in certain strains of mice, no
autoimmunity-related adverse events have been reported to date in clinical trials
utilizing Hsp vaccinations (49, 60). Other major antigen targets that should be
considered for immunotherapy with recombinant Hsp vaccinations are neoantigens
resulting from oncogenic mechanisms, such as E6 and E7 proteins found in human
papillomavirus-driven head and neck cancers, and the BCR-ABL fusion protein from
chromosome rearrangement that is common in chronic myeloid leukemia. These unique
proteins with neoepitopes not found elsewhere in the body are referred to as tumorspecific antigens (TSAs). They represent attractive targets for Hsp vaccination due to
their diminished risk for off-target autoimmunity, and the chance for a potent immune
response not hindered by tolerogenic processes in the body. Indeed, recent studies
suggested a strong correlation between patient response to immune checkpoint
inhibitors and the presence of tumor microsatellite instability. It is hypothesized that the
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microsatellite instability is a mechanism for rapid chromosomal rearrangement
responsible for the production of neoantigens (61, 62). However, not all cancers
express highly immunogenic neoepitopes available for generating specific antitumor
immune responses.
In addition to full-length protein antigens, antigenic peptides can also be
complexed to Hsp for cancer vaccination. For example, the large Hsp-TRP2175-192
peptide complex readily induced a potent TRP2175-192 cytotoxic T-lymphocyte (CTL)
response. However, the protective antitumor efficacy induced by such a peptidetargeted vaccine is much weaker than that achieved by the chaperone vaccine targeting
the TRP2 protein (57). This superiority of protein antigen-targeted vaccination may be
due to multiple antigenic epitopes inherent to a whole protein, providing APC many
opportunities to produce a peptide that will fit into its major histocompatibility complex
(MHC) and generating T helper signals for optimized or sustained CTL activation.
Considering the heterogeneity of human MHC allotypes, possible human leukocyte
antigen (HLA) restrictions as well as the differences between individual peptides,
vaccination with large Hsp-protein antigen complexes may prove to be more effective
for a wider variety of patients.
Targeting single antigen or epitope clearly has its disadvantage in the treatment
of heterogenous cancer cell populations. Advances in next generation sequencing and
bioinformatics are now beginning to mitigate some of the shortcomings associated with
using recombinant Hsp-TAA complexes and the ambiguity of selecting peptide targets
for different cancers and patients. There are several in silico prediction tools for tumor
protein or peptide sequencing, aiding in predicting HLA binding of specific tumor
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antigens, and T-cell receptor sequencing for analysis of the T-cell antigenic repertoire
after immunotherapeutic interventions (63).

Immunostimulatory Features of Hsp
Clinically significant antitumor immunity is dependent upon the activation of tumorspecific CD8+ T-cells by APCs that have taken up TAAs. MHC I molecule is present on
all nucleated cells and functions to randomly present endogenous peptides for the
purpose of intracellular immune surveillance. MHC II molecule, on the other hand, is
expressed only on APCs. It functions to present exogeneous peptides from
phagocytosed pathogens and dying cells to other cells of immune system. The peptide
binding cleft of MHC I is smaller (8-11 amino acids) and it is restricted to interactions
with the T-cell receptor (TCR) of CD8+ CTLs (64). MHC II, on the other hand, has a
larger peptide binding groove (13-17 amino acids), and is restricted to interactions with
CD4+ helper T-cells. ‘Cross-presentation’ is the less-understood process by which
internalized antigens from the extracellular environment, typically loaded onto the MHC
II complex, are instead shuttled to a pathway that results in formation of MHC I
complexed with processed peptide epitopes for priming CD8+ T-cells. This crosspriming process greatly facilitates the generation of antitumor CD8+ T-cells by allowing
their direct activation in the lymph node by APCs that have captured exogenous TAAs,
such as the case of cancer vaccination with tumor-derived Hsp preparations (64).
Indeed, one of the critical features of Hsp in cancer immunotherapy is their capability to
introduce associated TAAs into the endogenous antigen-processing pathways for crosspresentation by APCs, e.g., dendritic cells (DCs) (65-67).
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The mechanism underlying Hsp-enhanced antigen cross-presentation is not well
understood. It has been shown that Grp170 can direct the chaperoned peptide into the
Rab5+EEA1+ static early endosomes, where the peptides are loaded onto the recycling
MHC-I molecules (68). Our study of the trafficking pathway of Grp170 complexed with
melanoma antigen gp100 revealed that the internalized chaperone complex gained
access to the ER following uptake by DCs (69). Strikingly, the Grp170-facilitated antigen
cross-presentation requires the ER-associated protein degradation pathway involving
Sec61, a protein quality control machinery in the ER, which targets antigen for
proteasome-mediated degradation in the cytosol and integration into the conventional
MHC I-restricted antigen-processing pathway. Our observation also suggests that
Grp170 chaperoning allows protein antigen to escape from lysosomal degradation and
facilitate its entry into the ER from the early endosomes, possibly through a “ERendosome fusion” structure. However, additional studies are necessary to fully define
the exact role of Hsp in antigen cross-presentation.
In addition to their cross-presentation promoting activity, Hsp upon release from
injured or stressed cells to the extracellular milieu are believed to serve as ‘danger’
signals or DAMPs to alert the immune system. Several studies suggest that Hsp bind to
toll-like receptor (TLR) 2/4 on the surface of APCs, stimulating the NF-ᴋB pathway
necessary for the activation of APCs and for the production of pro-inflammatory
cytokines. Specifically, binding of Hsp to DCs or macrophages increases their
expression of maturation markers and co-stimulation molecules such as CD80, CD86
and CD40 as well as the pro-inflammatory cytokines IL-6 and TNF-α (70). The
expression of these co-stimulatory molecules represents the additional signals required
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to prime antitumor T-cells and to prevent immune tolerance during antigen presentation
(71-74). However, other studies suggest that contamination of recombinant Hsp with
lipopolysaccharide, the natural ligand for TLR2/4, may explain the reported Hspassociated TLR activation (75). While this confounding variable has complicated the
issue of whether Hsp themselves retain innate-stimulatory activity, additional studies
using different experimental models instead of Hsp-derived from bacteria protein
expression systems continue to support this intrinsic immunostimulatory feature in Hsp
(76, 77). Further supporting evidence demonstrates that cancer cells engineered to
secrete GRP170 were more efficient than unmodified cells in stimulating DCs to
produce TNF-α (78). It has also been reported that high doses of Hsp-TAA complexes
are capable of inducing immune-tolerance by expansion of regulatory T-cells, which
suggests that any endogenous DAMP activity carried by Hsp may be insufficient to
stimulate APC activity on their own (79, 80). Therefore, Hsp-based antitumor
vaccination may be considerably enhanced by the integration of pathogen-associated
molecular patterns (PAMPs) or microbial signals capable of activating the TLRs or other
signaling pattern recognition receptors on APCs.

Scavenger Receptors and Hsp in Immune Modulation
Scavenger receptors (SRs) were originally defined by their ability to bind to modified
lipoproteins and facilitate their removal from the extracellular environment. However,
members of this family of receptors can bind to a wide array of non-self or self-ligands,
including lipopolysaccharide, lipoteichoic acid, double stranded DNA (dsDNA), Hsp,
dying cells or apoptotic bodies. SRs are primarily expressed on APCs such as myeloid
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cells but are also reported to be present on endothelial cells (ECs) and fibroblasts (8183). SRs can be categorized into multiple classes based on their sequence similarities
or shared structural features, but there is little or no sequence homology between the
different classes of SRs (84). Early studies support the important roles of SRs as major
innate pattern recognition receptors in tissue homeostasis and host defense against
microbial infection (81). Investigations of the binding structures of Hsp vaccines on the
surface of APCs have led to the discovery of their previously unrecognized functions in
mediating antigen uptake and cross-presentation, as well as myeloid cell polarization
and APC activation (83). While SRs are required for recognizing, binding, and
internalization of Hsp-TAA complexes, different SRs appear to have different levels of
specificity for Hsp species and may control the fate of any TAAs to which they bind.
Therefore, involvement of specific SRs in the uptake of different TAAs may have distinct
immunological consequences, potentially determining the antitumor efficacy of Hspbased vaccination (83).
Class A SRs are characterized by one or more collagen domains as well as a
possible C type lectin (CLEC) and/or a type A scavenger receptor cysteine rich (SRCR)
domain (81). Scavenger receptor A (SRA), also called macrophage scavenger receptor
1 or CD204, is the prototypic member of this class. SRA is believed to bind ligands
through its SRCR while its collagen domain is dedicated to mediating interactions with
binding partners. Using in vitro systems, we and others have demonstrated that SRA is
required for uptake of Hsp110, Grp94, and Grp170 by APCs and subsequent crosspresentation of Hsp-associated antigens (85, 86). Unexpectedly, we found that genetic
ablation of SRA in mice strongly promoted antitumor immune responses generated by

11

autologous tumor-derived Hsp, recombinant Hsp-antigen complex, or TLR4-targeting
cancer vaccines, indicating an immunosuppressive role of SRA in antitumor immunity
(87, 88). Further mechanistic studies reveal that SRA expression in DCs dampens their
immunostimulatory function by interfering with the NF-B activation. This reduces
expression of co-stimulatory molecules and pro-inflammatory cytokines or chemokines,
thereby attenuating tumor-reactive CTL response in vivo (89-92). Not surprisingly,
downregulation of SRA expression in DCs markedly improves the immunogenicity of
DC-based vaccination and resultant antitumor immunity (93). In addition, the overall
level of this receptor in the tumor has been reported to correlate with poor prognosis in
human cancer patients (83). Other than its role for negative regulation of DC function,
this may also be due to its ability to contribute to macrophage M2 polarization through
ER stress signaling or by its ability to sequester interferon regulatory factor 5, a master
regulator of pro-inflammatory gene expression in myeloid cells (94, 95). While SRA on
DCs or macrophages clearly presents an opportunity for immunotherapeutic targeting,
the relevance of endothelial and fibroblast SR expression also deserves consideration
due to the reports that these cell types can function to suppress antitumor immunity by
directing deletion of antigen-specific CD8+ T-cells (82, 96).
Lectin-like oxidized LDL receptor 1 (LOX-1), the only member of the class E SRs,
has a single CLEC domain and is primarily expressed on ECs, B cells, macrophages,
and DCs (81). This SR appears to play an important permissive role in the antitumor
activity of CD103+BATF3+ DCs and T-cell priming in response to Hsp70-TAA complexes
or apoptotic bodies induced by radiation (97, 98). LOX-1 has been shown to bind to
Hsp70 and direct their associated antigens to the endogenous cross-presentation
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pathways. Furthermore, anti-LOX-1 antibodies inhibit Hsp70-TAA complex induced Tcell mediated antitumor immunity. Although the data remains limited, LOX-1 may
represent a preferable pathway for the processing of Hsp-TAA complexes to mount an
antitumor CTL response.
Scavenger receptor expressed by endothelial cells-I (SREC-I) is a member of
class F SRs that often have multiple epidermal growth factor (EGF) and EGF-like
domains (81). SREC-I can bind to multiple chaperones including Hsp70, Hsp90,
Hsp110, Grp170, and calreticulin (86, 99-101). Additionally, SREC-I expression is
elevated on DC exposed to Hsp70-TAA based vaccine. Whether this SR has a
permissive or suppressive effect on antitumor immunity generated by Hsp-TAA has yet
to be explored in a therapeutic setting in vivo. However, given its wide range of Hspbinding partners, exploring SREC-I function in the context of Hsp-based immunotherapy
is an attractive future research direction.
Stabilin-1 is a member of class H SRs that contain multiple EGF and EGF-like
domains, a fasciclin-1 and LINK domains, and a hyaluronan- binding domain typical of
proteins that interact with the extracellular matrix (81). Stabilin-1 is constitutively
expressed on lymphatic ECs and tissue resident macrophages but can also be induced
on vascular endothelial cells in response to inflammation. Stabilin-1 on APCs has been
shown to bind to Hsp70-TAA complexes and to mediate their internalization (99).
However, the overall effect of this SR on antitumor immunity induced by Hsp70-TAA
vaccination is unclear. Interestingly, stabilin-1 knockout or blockade reinvigorates T-cell
response to solid tumors by reducing tumor-infiltrating immunosuppressive cells and
enhancing recruitment of effector T-cells (102). Other studies linked this SR to
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mobilization of regulatory T-cells by ECs as well as the immunosuppressive function of
tumor-associated macrophages (103, 104). Although its role in Hsp-based vaccination
has not been thoroughly investigated, stabilin-1 has been implicated in multiple
immunosuppressive processes of the cancer-immune cycle. Therefore, Hsp-based
immunotherapy may benefit from blockade or pharmaceutical inhibition of this receptor.
LDL receptor-related protein 1 (LRP1/CD91) is a type 1 transmembrane receptor
that is expressed on the surface of APCs such as macrophages and DCs. Similar to
SRs, CD91 partners with many different co-receptors on the cell surface to facilitate
endocytosis of structurally diverse ligands and to modulate the resulting immune
response. Unlike other endocytic receptors for Hsp, CD91 can directly transmit
immunostimulatory signals upon phosphorylation of its cytoplasmic domain. Although
the complete signaling apparatus associated with CD91 remains to be elucidated,
engagement of this receptor results in immunostimulatory cytokine expression via the
activation of NF-B and p38, as well as phosphorylation of ERK and PI3K (105-107).
This receptor has been suggested to be a common receptor for Grp94/Gp96, Hsp90,
Hsp70, and calreticulin, which is necessary for cross-presentation of tumor antigens
chaperoned by these Hsp and can directly stimulate NF-B and p38 in response to its
Hsp ligands (106). To what extent CD91 partners with other known Hsp receptors for
modulation of Hsp-induced T-cell response is currently unknown. It is likely that other
receptors also participate in this coordinated process, because Hsp stimulation of
myeloid cells results in the production of cytokines not regulated by CD91.
Although these SRs are identified as Hsp-binding molecules on APCs, the
individual SRs appear to display distinctly different effects on antitumor immune
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responses elicited by Hsp-based anticancer vaccination or possibly immunotherapy in
general. Although the different classes of SRs are structurally unrelated, their ligand
binding domains share a common motif: centrally located cationic clusters surrounded
by anionic residues. This, along with the preference of many SRs to bind to anionic
ligands, suggests that SR-ligand interactions are electrostatic in nature (81). In addition
to allowing for ligand binding, the involvement of a specific SR during antigen uptake is
likely to affect the trafficking and processing of antigens inside the cell. For instance,
this can determine whether an internalized antigen carried by Hsp is silently degraded in
the lysosomes or shuttled into endogenous antigen-processing pathways for crosspresentation by MHC I molecules. Additionally, SRs have been demonstrated to alter
the cytokine response of APCs to different antigens, making their potential impact on Tcell differentiation and function especially relevant (106). The diversity of SR
functionality may also be compounded by the fact that many SRs participate with other
receptors in large signaling complexes termed “signalosomes.” This capacity for
cooperative actions further enhances functional versatility of these receptors, making it
possible for an individual SR to play different roles on the surface of various cell types
(81). As a result, other than optimization of antigen presentation and APC activation,
rational design of Hsp-based tumor vaccination requires careful consideration of their
interactions with these receptors.

Clinical Trials of Hsp-based Cancer Vaccines
The promising preclinical results of Hsp-based immunotherapies have led to multiple
clinical trials to date, some of which have yet to be completed and published. In a phase
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II trial of autologous tumor-derived Grp94/Gp96-peptide vaccination (HspPC-96,
Vitespen or Oncophage) paired with granulocyte-macrophage colony stimulating factor
(GM-CSF) and interferon (IFN)-α for the treatment of metastatic melanoma, 11 of 18
patients with measurable disease post-surgery showed disease stabilization. Addition of
IFN-α and GM-CSF did not enhance the vaccine effects compared to vaccination alone
(108). The autologous Grp94/Gp96-peptide complex vaccine has also been tested in a
phase III trial for the treatment of stage IV melanoma patients. Results of the trial
showed that there was no difference in overall survival between the standard of care
and the Grp94/Gp96 vaccination. However, a more detailed patient subclassification
revealed a survival benefit for the early-stage IV melanoma patients (M1a, distant skin,
subcutaneous or nodal metastasis; M1b, lung metastasis) (109). This autologous
Grp94/Gp96 vaccine was also recently tested in a phase II multi-center trial for treating
patients with recurrent glioblastoma post-surgery. The treatment resulted in a median
overall survival of 42.6 weeks, with 90.2% of patients surviving longer than 6 months,
which is improved compared to historical controls (110). Currently, two randomized
trials are open to assess survival in recurrent glioblastoma patients receiving the
Grp94/Gp96 vaccine plus Bevacizumab or plus standard treatment (RT and
temozolomide) vs. patients receiving Bevacizumab or standard treatment alone.
The large Hsp110-gp100 protein antigen complex has also been investigated in a
phase I trial through the National Cancer Institute Rapid Access to Intervention
Development or RAID program. Patients with recurrent and advanced stage melanoma
were vaccinated with different doses of recombinant human Hsp110-gp100 complex

16

vaccine as seen in the pre-clinical studies (45, 57). The immune correlative studies
have been completed and are under review.
An ex vivo Hsp70 activated NK-cell therapy was tested in a phase II trial for
treatment of patients with non-small cell lung carcinoma who were refractory to cisplatin
and RT. Patients in the trial first underwent leukapheresis to have their NK cells
expanded and stimulated with Hsp70 peptide and low doses of IL-2 ex vivo, and then
were re-infused with the activated NK cells. There was only moderate clinical activity
observed, perhaps due to the advance stage of the disease. However, immunological
activity was evident and generally well tolerated in all patients (111).
Two ongoing clinical trials use allogenic injections of irradiated human lung
cancer cell lines transfected to secrete Grp94/Gp96 (HS-110; viagenpumatucel-L) or
OX40 antibodies (HS-130) with agonistic activity for co-stimulatory molecules on T-cells.
In the current phase Ib/II (DURGA trial), HS-110, the allogenic cell line expressing
Grp94/Gp96 will be irradiated and used to vaccinate patients in combination with ICB.
The second clinical trial is testing the combined HS-110/HS-130 treatment for
concurrent vaccination and co-stimulation.

Next-generation Hsp-based Immunotherapy
Although numerous studies have documented the intrinsic innate-immunostimulating
property of Hsp, this effect in most cases is very modest and may not be adequate to
efficiently mount an adaptive antitumor immune response. Given that pathogen-sensing
signaling pathways in APCs are instrumental in bridging innate and adaptive immune
responses, its use may aid in driving robust T-cell activation. Therefore, integrating
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PAMPs into Hsp-based antigen delivery cargo could further promote immune activation
(112). Recently, we engineered a chimeric Hsp molecule, termed Flagrp170, by fusing a
defined NF-κB-stimulating sequence from the NLRC4 and TLR5 agonist flagellin to the
chaperone GRP170. This molecular engineering takes advantage of the superior
antigen-binding capacity of the large Hsp and the NF-κB-stimulating activity of microbial
signal to create a next-generation Hsp-based immunotherapeutic agent with enhanced
immunogenicity. This unique molecule in the form of protein or DNA can be used to
develop multimodal immunotherapeutic applications, including recombinant chaperoneTAA protein complex vaccine, DNA vaccine, cancer cell vaccine, and viroimmunotherapy.
Inspired by the first cancer immunotherapy conducted by Dr. William Coley who
successfully treated his patients with intratumoral injections of microbial materials in late
1800s, we recently evaluated the therapeutic efficacy of intratumoral administration of
an adenovirus expressing Flagrp170, Grp170, or flagellin (113). We demonstrated that
Flagrp170 is much more potent than either Grp170 or flagellin alone in eliciting a robust
antitumor response in models of melanoma, colorectal, and prostate cancer. This
therapeutic activity is dependent upon BATF3+ DCs, CD8+ T-cells, and NK cells as well
as Gm-CSF, IL-12, and IFN-. Furthermore, this local treatment generates a systemic
immune response capable of eradicating distant metastases (114, 115). Given the
presence of abundant TAA/TSAs present in the tumor sites, this Flagrp170-based insitu vaccination may be used to generate CTLs directed against the entire antigenic
repertoire within the tumors. Since the ER retention KDEL motif has been removed from
native Grp170, this allows for constitutive secretion of Hsp-TAA/TSA complexes from
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infected cancer cells. Hsp-TAA/TSA complexes targeting APCs with the NK-Bstimulating ‘danger’ signal carried by the chimeric Flagrp170 molecule will help optimize
antigen cross-presentation and T-cell activation (115). A recent study published from
our lab showed the mechanistic importance of the Nod-like-receptor CARD domaincontaining protein 4 (NLRC4), which functions as the intracelluar cytosolic pathogen
senseing pathway for flagllin. In this publication we discovered that NLRC4 was more
critical than TLR5 for the immune protection generated by Flagrp170, and that Gm-CSF
produced by CD8 T-cells after Flagrp170 was indespensable in generating antitumor
immunity. We hypothesis that since Flagrp170 is delivered virally, the cytosolic pattern
recogniation receptor NLRC4 would likely be the target of immune activation as
opposed to the membrane expressed TLR5 (116). Although studies are still ongoing to
better understand the molecular and cellular alterations within the tumor
microenvironment following administration of this novel agent, our results strongly
support the use of this next-generation Hsp molecule for improved vaccine development
as well as for reprograming the tumor immune compartment to covert immunologically
‘cold’ tumors into ‘hot’ ones. Furthermore, future studies using this platform will assess
the feasibility of combining this agent with other conventional treatment modalities for
improved therapeutic outcomes.
Another recently created Hsp fusion molecule involved the modification of M.
tuberculosis derived Hsp70 fused to a single chain variable fragment (scFv) antibody
specific for mesothelin, an antigen expressed primarily in mesothelioma and ovarian
cancer. This fusion protein, called scFvMTBHsp70, takes advantage of the inherent
immunogenicity and peptide-chaperoning capacity of the M. tuberculosis-derived
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Hsp70, allowing its delivery to the tumor microenvironment with the mesothelin-specific
antibody. scFvMTBHsp70 has been shown to increase survival in ascites models of
mesothelioma and ovarian cancer in a CD8+ dependent manner (117, 118). However, it
remains to be determined whether the strong immunogenicity of microbial Hsp70 results
in immune side effects in patients.

RT and Immune Activation
Whether the intent is curative or palliative, most cancer patients with solid tumors will
undergo some form of RT during their course of treatment. The bulk of irradiated cancer
cells die due to mitotic crisis caused by continued cell cycling in the presence of DNA
double strand breaks. These breaks are caused by either direct attack by high-energy
photons, or by reactive oxygen and nitrogen species generated as a consequence of
ionization events (12). Despite the well-recognized cytotoxic and cytostatic effect on
cancerous cells, it is becoming increasingly appreciated that the durable control of
tumor by RT may involve the function of the host immune system (119, 120). In very
rare and sporadic reports, local RT results in regression of distant lesions or metastases
outside of the scope of the field of radiation. This phenomenon, termed the ‘abscopal’
effect, is believed to be attributed to the systemic antitumor immunity activated by RT
(12, 121). The mechanisms underlying RT-induced antitumor immune responses are
complex and most likely involve active interplays between irradiated cancer cells and
the tumor immune compartment.
Multiple investigations have mostly attributed to the immunostimulatory effect of
RT to an altered repertoire of TAAs available in the tumor microenvironment and
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activation of tumor-infiltrating innate or adaptive immune cells. Radiation-induced
exposure of antigenic peptides have been identified as a possible mechanism
underlying RT-elicited antitumor immune response (15). Additionally, RT can trigger the
‘danger’ signals within the tumor microenvironment, such as immunostimulatory
cytokines, to potentiate cross-presentation of TAAs by activating DCs (122). Recently,
RT has been shown to induce the production of type I IFNs through activation of
intracellular DNA sensors, i.e., the cGAMP synthase-the cytosolic DNA-sensing
stimulator of interferon genes (STING)-dependent pathway (123, 124). The STING
pathway plays an essential role for CD8+-mediated antitumor responses (17). Upon
binding to damaged self or foreign dsDNA, the pattern recognition receptor the cGAMP
synthase catalyzes the production of cyclic GMP-AMP which then binds to the adaptor
protein STING. STING translocates to the perinuclear space, binds to TBK1 and IRF3,
leading to their phosphorylation and the subsequent production of IFN-β (125, 126).
This type I IFN signaling is critical for the maturation and recruitment of CD103 +BATF3+
DCs necessary for development of antitumor immunity (123, 127-133). This response
can also occur spontaneously in tumors that exhibit chromosomal instability, and preexisting activation of this pathway has been linked to patient responses to ICBs,
providing further context for the rational combination of RT and immunotherapy (134). In
addition to DC activation and T-cell priming, RT can also remodel the tumor vasculature
to facilitate lymphocyte extravasation and recruitment via upregulation of vascular cell
adhesion molecule-1 and chemokine CXCL16 (135-137).
Although immunostimulatory effects of RT have been well documented, they are
for the most part not sufficient to engage an effective antitumor immune response to
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eradicate poorly immunogenic cancers. This may be caused by an immunosuppressive
tumor milieu dominated by regulatory T-cells, myeloid-derived suppressor cells
(MDSCs), and M2-polarized macrophages (10, 18, 138, 139). In addition, RT itself also
elicits immunosuppressive factors that can dampen the effector functions of immune
cells. Activation of TGF-β by RT has been shown to impair CTL function, and RTinduced expression of chemokine stromal-derived factor-1 can recruit tumor-promoting
and immunosuppressive myeloid cells (140-142). These immunoregulatory events may
explain why the ‘abscopal’ effect of local RT remains extremely rare in the clinic.
Nonetheless, strategic targeting of the major steps of the cancer-immune cycle may be
exploited to augment systemic antitumor immunity in the setting of RT to amplify or
reproducibly generate an abscopal response (21).

Immune Targeting of Hsp for Enhanced RT
Immunogenic cancer cell death (ICD) has been proposed to be a major mechanism
involved in RT-induced antitumor immunity (143). ICD is often associated with surface
expression or secretion of ‘immunogenic signals’ that fall in the category of DAMPs. RT
has been shown to trigger translocation of the ER-resident chaperone calreticulin to the
cancer cell-surface, which serves as an ‘eat me’ signal and enhances the
immunogenicity of cancer cells (144, 145). DAMPs also allow efficient communication of
the ‘antigenic pattern’ of dying cancer cells to the host immune cells and thereby
eliciting potent antitumor immunity. Indeed, induction of an ER stress response,
characterized by marked elevation of ER-resident chaperones (e.g., Grp94/Gp96,
Grp170), has been identified as one of common features of ICD. Considering that
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radiation exposure can induce the expression and release of Hsp that can serve as
DAMPs as well as the cargo of TAAs, it is conceivable that these extracellular Hsp
participate in the adaptive immune response by promoting antigen cross-presentation
and T-cell priming (146). However, to what extent these Hsp can help with antitumor
immunity during RT has not been thoroughly explored.
Several studies from our lab have shown that genetically engineering cancer
cells to either overexpress or secrete the large Hsp (i.e., Hsp110, Grp170) dramatically
increases tumor immunogenicity. Immunization of mice with these irradiated cancer
cells provided preventative and therapeutic anticancer effects in multiple tumor models
(78, 147, 148). The improvement of antitumor efficacy by ectopic expression of secreted
Hsp appears to depend on CD8+ T-cells and NK cells. In addition, this strategy
effectively expanded T-cell diversity for TAAs antigens, suggesting that passively
released Hsp may be insufficiently immunogenic to drive a CTL response. Thus, active
Hsp-targeting approaches aimed at increased DAMP signals as well as processing and
presentation of TAAs could be an effective avenue to expanding the T-cell repertoire
during RT (147).
Exosomes are 80-200 nm vesicles constitutively produced by all mammalian cell
types. They are formed by inward budding of specialized endosomal compartments
called multivesicular bodies and known to mediate cellular communications (149, 150).
Similar to Hsp, exosome production can be enhanced during states of cell stress (151).
Although it is unclear whether these proteins reside in the lumen or are associated with
the exosomal membrane, Hsp such as Hsp70 and HSC70 are consistently detected in
exosomes, and have served as reliable exosomal markers since their original discovery

23

(152). These exosomes also contain TAAs and can be taken up preferentially by splenic
DCs (153). However, the immunoregulatory role of these Hsp within the tumor-derived
exosomes is unclear. A recent study showed that exosomal membrane bound Hsp72
suppressed antitumor immunity by stimulating signal transducer and activator of
transcription 3-dependent immunosuppressive activity of MDSCs (73). However, it has
also been reported that tumor-derived exosome vaccines generated potent antitumor
immunity, which can be further enhanced when exosomes were prepared from cancer
cells that experience heat shock or other cellular stresses (154). Indeed, our previous
work demonstrated that Hsp110 isolated from thermally stressed cancer cells was more
immunogenic in stimulating an antitumor immune response than those from untreated
cells, suggesting that heat shock may alter Hsp-carried antigenic profiles and impacts
on Hsp-induced antitumor immunity (44).
Upon exposure to radiation, cancer cells undergo enhanced secretion of
exosomes in a p53 dependent manner (151, 155, 156). In addition to Hsp and TAAs,
exosomes derived from cancer cells exposed to hypofractionated radiation are capable
of transferring STING stimulatory dsDNA to DCs, resulting in activation of type I IFN
response. Mice vaccinated with the exosomes from irradiated tumor cells were shown to
induce a potent antitumor immune response (153). Intriguingly, Grp170 not only bind to
client proteins or polypeptides, but also can chaperone DNA substrate, such as
microbial CpG oligodeoxynucleotides. Forming a complex of GRP170 and CpG
oligodeoxynucleotides can significantly enhance activation of TLR9 signaling (157). It is
of interest to examine Hsp-associated with tumor-derived exosomes and their
immunoregulatory activity that may be altered by radiation-induced genotoxic stress as
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well as potential Hsp interaction with dsDNA. Considering the ability of RT to enhance
expression of unique TAAs for incorporation into exosomes, the study of the
immunogenicity of tumor-derived exosomes as well as exosomal Hsp in the setting of
RT may produce novel tools to help integrate RT and Hsp-targeting immunotherapies
(15, 153, 158).
Membrane bound Hsp70 induced by RT may serve as tumor-specific targets for
NK cells, sensitizing irradiated cancer cells to ICD (146). In their unstressed state,
mammalian cells present non-classical HLA-E molecules with bound HLA-A, HLA-B,
and HLA-C leader peptides on their surface. They bind to the CD94/NKG2A inhibitory
receptor complex and inhibit the activation of NK cells. In response to RT or
chemotherapy, Hsp70 in some cancer cells will translocate to the outer leaflet of their
plasma membranes to interact with phosphatidylserine (159). A Hsp70-derived signal
peptides compete with the leader peptides for binding to HLA-E, thereby disrupting
CD94/NKG2A activity and promoting cytolytic function of NK cells (146). Treatment of
membrane Hsp70+ non-small cell lung carcinoma patients with autologous NK cells ex
vivo activated with Hsp70-derived signal peptide and IL-2 is currently being tested in
clinic (111).
Given the development of next-generation Hsp-based immunotherapeutic agents
(i.e., Flagrp170) that are engineered to carry a defined microbial signal, administration
of such a hybrid molecule of PAMP and DAMP to the tumor sites during RT could
greatly improve the ICD. The feasibility and therapeutic efficacy of intratumorally
delivering Hsp as well as this chimeric Hsp has been experimentally established in
mouse cancer models (115, 160). The uniquely combined actions of Flagrp170 in

25

facilitating antigen cross-presentation while concurrently delivering a microbial
immunostimulatory signal for optimized antigenicity and co-stimulation should strongly
provoke ICD upon irradiation. Our previous work showed that CD8+BATF3+ DCs were
required for the therapeutic efficacy of Flagrp170-based in situ vaccination (115).
Several lines of evidence suggest that radiation treatment may be harnessed to expand
or recruit CD103+BATF3+ DCs to the tumor sites to further drive ICD together with Hspbased immune reprograming of the tumor (17, 161, 162). Studies are ongoing to
evaluate this novel agent in the context of RT for its potency to induce an abscopal
effect via systemic mobilization of innate and adaptive immune arms.
As a major Hsp-binding receptor, SRA was shown to negatively regulate the
immunogenicity of mouse cancer cells treated by ionizing radiation, supporting a
scientific rationale for combining RT with SRA-blocking therapy (91). Our subsequent
study demonstrated that intratumoral administration of SRA-silenced DCs enhanced the
treatment outcome of RT against mouse prostate cancer and metastases, which was
mediated by IFN-γ-producing CTLs (163). Together with the data on the impact of SRA
on Hsp-based cancer vaccination, it is evident that SRA plays an important role for
determining the immunogenicity of both Hsp-based vaccines and dying cancer cells
during RT. Therefore, pharmacologic, genetic, or biological approaches to targeting
SRA should be considered when combining RT and Hsp-based immunotherapy.
Together, these findings suggest that their combination could strengthen the ICD
signals, deliver target antigens, and overcome the immune dysfunction in the tumor
microenvironment following RT.
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Over the past few years immune checkpoint inhibitors targeting cytotoxic
lymphocyte antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligands
PD-L1/2 have changed the treatment paradigms in medical oncology. Several
antibodies (e.g., ipilimumab, nivolumab, pembrolizumab) targeting these T-cell
suppressive immune checkpoint pathways have been approved by the US FDA and
have been shown to improve overall survival for patients with certain
metastatic/recurrent cancers (164, 165). Given the immunoregulatory effects of RT
through diverse mechanisms, a logical next step is to combine RT and ICB therapy to
reverse cancer-mediated immunosuppression and potentiate durability of an antitumor
immune response. Currently, there are hundreds of phase I-III clinical trials testing this
combinatorial therapy in patients with different malignancies or at different stages. While
these studies are expected to provide important insights regarding feasibility and
benefits of combined RT and ICB in the clinic setting, the clinical trials should be
designed to ensure combination treatments are supported by scientific rationales and
experimental evidence (10, 139). In a recently completed phase III trial that evaluated
RT combined with anti-CTLA-4 therapy in metastatic castration-resistant prostate
cancer, its primary endpoint was not met, indicating that additional approaches must be
considered to improve the overall treatment outcome (166). Indeed, collective preclinical and clinical evidence suggests that tumors responding to immune checkpoint
inhibitors tend to exhibit a “T-cell inflamed” phenotype prior to the initiation of treatment
(167-170). These reports highlight the potential for Hsp-based cancer vaccination
platforms to expand pre-existing antitumor T-cell repertoires, and reprogram the
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immune landscape of immunologically ‘cold’ tumors, to improve clinical response rates
of ICB therapy.

Head and Neck Squamous Cell Carcinoma (HNSCC) Application
Head and neck cancer (HNSCC) cases are projected to increase by 30% over the next
decade globally, and it is the sixth most common cancer diagnosis in the world (171).
While overall survival remains high particularly in human papilloma virus (HPV) positive
HNSCC cases, the overall survival rate has remained stagnant at around 60% over the
past decade (172). According to the surveillance epidemiology and end results (SEER),
overall survival is around 60%, however, more than half of patients diagnosed yearly
present with distant or metastatic disease, which significantly drops the five-year
survival rate. Additionally, survivors of this disease have the second highest rate of
suicide amongst all cancer patients (63.4 cases per 100,000), because of the poor
quality of life, impart of the aggressive treatment regimens that confer a high survival
rate (173). Biomarkers associated with improved outcomes like the expression of E6
and E7 oncoproteins seen in HPV+ HNSCC, are known to target p53 and the
retinoblastoma associated protein (Rb) proteins for ubiquitination and degradation,
respectively. These activities push cell cycle progression past the restriction point,
which drives the creation of a malignant neoplasm. This HPV driven event is
characterized by increased P16ink4a as a result of Rb degradation caused by the E7
protein (174). The upregulation of P16ink4a seen via immunohistochemistry serves as a
surrogate marker for the clinical diagnosis of HPV+ HNSCC, and is a known inhibitor of
cyclin D, and cyclin dependent kinase (CDK4/6) (175, 176).
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Treatment regiments for HNSCC are multimodal and include surgical intervention as the
typical first line therapy. RT doses range from 62-72Gy delivered in 2-2.5Gy fractions
five days a week, often in combination with cisplatin-based chemotherapy (177). The
treatment regimen selection depends upon several factors. The cancer stage, known
extent of metastasis, and the primary sites of origin dictate what treatment modality will
yield the most clinical benefit for survival and quality of life. Typically, patients
presenting with a localized primary tumor and no metastasis to the lymph nodes,
receive a monotherapy of either surgery, or RT. This cohort of patients will benefit from
cure rates of greater than 80% with monotherapy treatment (178). However, there are
reports of cases where a small, yet invasive primary tumor producing nodular
metastasis are more easily identified by elective neck dissection as opposed to RT
(179). The selection for a surgical intervention occurs mostly in patients with
malignancies in the oral cavity (171). Whereas, RT is typically used in deeper locations
like the pharynx or larynx, which have shown an increased response rate with hypofractionated doses as oppose to the conventional RT regimen (180, 181). In patients
with aggressive invasive tumors, increased tumor burden, or perineural invasion, postsurgical cisplatin chemotherapy and RT (chemo-radiation) offer significantly higher
overall survival (OS), and lower tumor re-occurrence risks (171, 182, 183). However,
the late effects of radiation therapy are more prevalent in patients who receive postsurgical chemo-radiation regiments, significantly lowering the quality of life after
treatment (184). Therefore, new treatment modalities that could lower the curative
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doses of RT or cisplatin therapy required will aid in reducing the late effects patients
experience after treatment.

Recently, ICB therapy has been approved as first line therapy in patients with advanced
metastatic disease, or recurrent disease. Patients are candidates if they have
undergone cisplatin therapy within six months, exhibit tumor microsatellite instability, or
if they have a PDL1 expression in the tumor. PDL1 tumor expression is measured via
immunohistochemistry, and the composite positive score (CPS) serves as the
quantitative clinical scale (ranging from 0-100) used for decision making regarding the
level of PDL1 expression (171). Contraindications for ICB include autoimmune
conditions or having received cisplatin therapy more than six months prior. Patients with
a CPS<1 are recommended a chemo-radiation regimen or clinical trials. Asymptomatic
patients with CPS>20 and low tumor burden are recommended ICB as a monotherapy
given the high PDL1 expression, or a clinical trial. However, patients with CPS range of
2-19 are recommended dual ICB and cisplatin therapy, or a clinical trial given their
moderate PDL1 expression. These clinical recommendations were founded upon the
KEYNOTE-048 clinical trial comparing Pembrolizumab (an antibody inhibiting PD-1)
verses combination of chemotherapy and cetuximab, or Pembrolizumab alone (185).
Comparatively across all patients (mixed CPS scores), Pembrolizumab as a
monotherapy compared to Pembrolizumab plus chemotherapy was inferior in terms of
OS (11.6 months vs. 13 months). However, in patients with CPS scores ≥20 or ≥1,
Pembrolizumab monotherapy was superior to chemotherapy plus cetuximab (OS 14.9
months vs. 12.3 months respectively) due to the increased tumor PDL1 expression
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conferring a likely response rate to the therapy. Furthermore, clinicians favor the use of
the combination of ICB (PD-1 inhibitors approved in HNSCC) and chemotherapy given
the increase survival rates with the dual implementation (171, 176, 178). This decision
is even more likely in patients with larger or bulky tumors given chemotherapy efficacy
as a de-bulking agent aids in improvement of immunotherapy generally. Alternatively,
patients with lower tumor burden are spared additional rounds of chemotherapy and are
treated with mono-ICB.

Next Generation Hsps Cancer Vaccines may Improve Clinical Response Rates
The constitutive expression of Hsp as molecular chaperones and their upregulation as
part of a stress response is crucial for maintaining cellular functions. The inherent
chaperoning property of these Hsp has provided a molecular basis for tumor-derived
Hsp preparations being used as cancer vaccines to elicit an antitumor immune
response against the tumor antigenic fingerprint carried by Hsp. This similar principle
has also been utilized to reconstitute Hsp-TAA complexes for targeted vaccination or to
genetically engineer cancer cells to produce Hsp-TAA complexes as cellular vaccines.
Hsp provide an attractive platform for vaccine therapy given their superior ability to
preferentially deliver TAAs to APCs for enhanced cross-presentation. The successful
pre-clinical studies of different forms of Hsp-based immunotherapies have led to
multiple phase I-II trials in patients with advanced malignancies. Although there were no
significant toxicities as expected, the results from the clinical trials of Hsp-based cancer
vaccination have been modest. While multiple reasons may be involved, it is evident
that new strategies for improving Hsp-based immunotherapies are needed. Our recently
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developed next-generation Hsp vaccine vehicle (i.e., Flagrp170) appears to be
promising in potentiating antitumor immunity and more importantly in reprograming the
immunosuppressive tumor microenvironment, allowing for enhanced T-cell infiltration
and cytotoxic activity. RT is a conventional treatment modality that is widely used in the
clinic to achieve local control of tumors in the irradiated area. In addition to the direct
cytotoxic effect on cancer cells through DNA damage, RT can induce an immunemediated antitumor response, exemplified by limited clinical cases of abscopal effect.
Given the distinct mechanisms of action, RT and immunotherapy hold the potential for
synergistic cancer management, therefore, many efforts have been made to pursue
rationally combined RT and immunotherapy. Encouraging preclinical data have
stimulated translation of this combinatorial modality. However, clinical data from trials
that combined RT with other immune modulating agents, e.g., ICB, vaccines, have only
shown a modest response. Due to the unique aspects of Hsp-mediated
immunomodulation, Hsp-based vaccination may strengthen the ICD during RT to
achieve reliable induction of abscopal effect for eradicating both irradiated and distant
metastases. Hsp-directed therapy can help provide the T-cell diversity that is critically
needed to target the heterogeneity often seen in human solid cancers. Particularly,
reshaping the tumor immune compartment using the next-generation Hsp-based
immunotherapeutic agent holds a promise in improving the immunogenicity of cancer
cell death during RT for personalized vaccination and augmenting systemic antitumor
immunity necessary for an abscopal therapeutic effect. However, the key to furthering
these multimodality treatment strategies will be to develop a better understanding of the
immunologic and genetic mechanisms that underpin the efficacy of different therapies.
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This will aid in the development of relevant predictive biomarkers that may help stratify
the patient populations that can benefit from this integrated approach. Questions also
remain regarding radiation parameters such as the timing, dose, and fractionating
schedule as well as the preferable disease setting to test combination strategies. It
should also be noted that RT itself can bring multiple immune-limiting factors, such as
immunosuppressive cytokines and the recruitment of MDSCs, alternatively activated
macrophages, and phenotypically tolerogenic APCs, which must be addressed before a
lasting tumor protective immunity can be achieved. Moreover, immune activation by
active Hsp-targeted vaccination often triggers immune checkpoint pathways (e.g., PD1/PD-L1) that will counteract the activity of immune effector cells (e.g., CTLs).
Therefore, integration of immune checkpoint inhibitors into the treatment protocol not
only will reinvigorate exhausting T-cells in the tumor microenvironment, but also can
further leverage on vaccination-expanded T-cell repertoire to maximize the full potential
of the combination RT-Hsp therapy regimens in the clinic.
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METHODS
Animals and Murine Cell Lines
Female C3H/HeN mice and C57BL/6 mice that were six to eight weeks of age were
purchased from Jackson Laboratory (Bar Harbor, Main, USA). The murine head and

33

neck squamous cell carcinoma cell line SCC VII was a kind gift from Dr. Gal Shafirstein
(Rosewell Park Comprehensive Cancer Center) and the MOC II cell line was a kind gift
from Dr. Joing Li (Virginia Commonwealth University). The SCC VII cells were cultured
in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 10mM 2-[4(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES free acid), 2mM Lglutamine, and 100U/mL penicillin, and 100µg/mL streptomycin antibiotics. SCC VII
cells were transfected to express whole OVA-albumin protein using a pCDNA3.1
plasmid containing OVA, with polyethyleneimine transfection as described by
manufacturer (Sigma Aldrich, Darmstadt, Germany). The MOC II cells were cultured in
Dulbecco’s Modified Eagle’s Medium F-12 supplemented with 10% FBS, 10 mM
HEPES free acid, 2 mM L- glutamine, 100 U/ mL penicillin, and 100 µg/mL
streptomycin. MOC II Luciferase/TD tomato expressing cells (MOC II Luc/Tdt) were
generated by lentivirus transfection and gentamicin selection from pcDNA3.1 plasmid
construct, a kind gift from Dr. Ross Mikkelsen. Cell lines were also routinely tested for
the presence of mycoplasma using a PCR-based method of detection (ATCC,
Manassas, Virginia, USA).
Generation of Replication Deficient Adenovirus
Replication deficient adenovirus was produced using 293A cells. The construct carried
human or mouse Grp170 with the ATP binding domain truncated, KDEL ER retention
sequence motif removed, and fused to the NFB activating domain from flagellin.
Flexible linkers were used to attach the NFB activating domain to Grp170 and a
signaling peptide aiding in secretion of the chimeric heat shock protein. Recombinant
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adenovirus was packaged and then purified using AdenoPack Maxi spin columns
(Sartorius Stedim Biotech, Bohemia, New York, USA) (115, 116).
In vivo Tumor and Immune Neutralization Studies
SCC VII cells were cultured and 2 x 105 cells were implanted subcutaneously in the
flanks of female C3H/HeN female mice 6-8 weeks of age. In abscopal effect
experiments, bilateral tumors were implanted and in single tumor models, only the right
flank was inoculated with SCC VII tumor cells. The right flank received 2 x 105
cells/injection and the left flank received 1 x 105 cells/injection if the metastatic model
was being used to demonstrate abscopal responses. Immune cell depletion
experiments were conducted by injecting animals intraperitoneally with monoclonal
antibodies (200µg) targeting CD4 or CD8 T-cells three days prior the beginning of the
experiment. Depletion antibody clones for CD8 T-cells (clone 2.43), CD4 T-cells (clone
Gk1.5), and IgG control was purchased from BioXcell (West Lebanon, New Hampshire,
USA). Tumors were measured by tumor volume, as defined by V = (shortest dimeter2 x
longest diameter)/2 producing tumor volume (mm3). Animals were euthanized once
tumors reached 2048mm3 in diameter as approved by the VCU Institutional Animal
Care and Use Committee (IACUC).
In vivo Stereotactic Radiation
Animals were anesthetized using isoflurane, imaged then irradiated using the Small
Animal Radiation Research Platform (SARRP) Xstrahl model (Suwanee, Georgia,
USA). A computerized tomography (CT) image was taken first to create an isocenter
dose of the animal’s tumor, dosimetry and planning was completed using MuriPlan from
SARRP as previously published (186). Stereotactic CT guided radiation was then
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delivered using a 10mm collimator, at either 2.5Gy/day or 10Gy/day for three
consecutive days depending upon the experimental model used in the experiment.
Flow Cytometry and ELISA
Tumors were digested using collagenase D (1mg/mL) and DNase I (40µg/mL) at 37°C
using the gentleMACS tumor dissociation machine (Miltenyi Biotec, Gladbach,
Germany). Tumor infiltrating leukocytes where then enriched using Percoll at a 40% and
70% gradient and centrifuged as recommended by the manufacturer (Sigma Aldrich,
USA). TILs or splenocytes for intracellular staining were stimulated in complete RPMI
medium containing phorbol 12’-myristat-13’acetate (PMA) at 10nM with ionomycin
(0.5µM) for three hours and then blockage of the golgi with brefeldin A (BFA) 5µg/mL for
two hours. Receptor staining occurred with live/dead zombie dye as manufacturer
recommendations, then CD16/32 block with 2.4G2 at 4°C for 15 minutes, followed by
the addition of receptor antibodies for staining in the dark for a duration of 30 minutes.
Cells were washed three times with PBS, and fixed with 4% paraformaldehyde for 15
minutes at 4°C in the dark. Cells were then prepared for permeabilization for 30 minutes
followed by the addition of intracellular antibody targets, plus 2.4G2 for an additional 30
minutes of staining. Cells were then washed three times with permeabilization buffer
and then fixed with 4% PFA for 15 minutes before resuspending with FACS buffer.
Flow cytometry antibodies used were the following: FITC granzyme B (clone Gb11),
FITC CD86 (GL-1), PE IFN-γ (XMG1.2), PE GM CSF (MP1-22E9), PE CD80 (16-10A1),
PE Cy7 CD44 (BJ18), APC CD45 (30-F11), BV421 TCR-β (H57-597), zombie dye aqua
live dead stain, BV711 CD62L (MEL-14), BV711 CD11c (N418), APC-FIRE750 CD4
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(GK1.1) (Biolegend, San Diego, California, USA) BUV395 CD8, BUV737 CD11b
(M1/70) (BD Bio sciences San Jose, California, USA).
Quantitative PCR Analysis (qPCR)
Real-time quantitative PCR was performed as previously described (115). In these
experiments RNA was extracted using TRIzol reagent (Thermofisher Scientific).
Reveres transcription and qPCR were performed using carboxylfluorescein FAMlabeled probed purchased from Thermofisher Scientific. Immune genes were analyzed
and normalized to β-actin and then experimental control groups using the standard 2 ΔΔCt calculation

formula.

Statistical Analysis
All data in this thesis was analyzed using Graphpad Prism 9 and were expressed in
mean SD or SEM values. Statistical significance between three or more groups was
determined via One-way ANOVA, statistical significance between two groups was
determined via a student’s t-test, and statistical significance between tumor growth
curves or survival was determined via Two-way repeated measures ANOVA or LogRank test respectively. Asterisks denote statistical significance of: * P≤ 0.05, ** P≤0.01,
*** P≤0.001, **** P≤0.0001.
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RESULTS
Ad. Flagrp170 Intratumoral Injections Potentiate RT, Synergizing to Promote
Antitumor Immunity.
Using the HNSCC carcinoma model SCC VII with syngeneic C3H/HeN mice, we studied
the ability of Flagrp170 to potentiate RT in vivo. The prominently used SCC VII model
tumor has been previously described to have a genetic profile akin to the human
disease state of HPV negative HNSCC (187). SCC VII cells transfected to express
OVA-albumin (SCC VII-OVA) were implanted subcutaneously (2x105cells/injection) and
then treated once tumors reached 8-9mm in diameter. Animals remained untreated or
were either treated with empty adenoviral vector (null), or adenoviral Flagrp170
intratumorally at a dose of 2 x 108 PFU/dose, q.a.d., for five doses. RT was delivered at
2.5Gy dose stereotactically for three fractions in succession using a Small Animal
Radiation Research Platform (SARRP). Flagrp170 combination with RT significantly
reduced tumor volumes as compared to combination null, and the no treatment (control)
groups (Figure 1A). Upon analysis of tumor infiltrating leukocytes, it was found that
Flagrp170 combination treated tumors had a significant increase of IFN-γ+ CD8+ T-cells,
and CD8+ effector memory (Em) T-cells (Figure 1b). Similarly, CD4+ T-cells displayed
an increase of IFN-γ+, TNF-α+, and Tem phenotype at the tumor site (Figure 1C). As a
metric of systemic immunity, splenocytes from tumor bearing mice were collected ex
vivo and stimulated with whole cell lysates (WCL) or OVA protein for 96-hours. The
combination of Flagrp170 treatment produced significantly higher levels of IFN- γ when
splenocytes were activated with both WCL or OVA protein as determined by ELISA
(Figure 1D). Gene analysis at the tumor site further supported a statistically significant
increase of IFN-γ and a trend towards significance in granzyme B levels in Flagrp170
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and RT combination group (Figure 1F). Furthermore, a dose response of RT delivered
in three fractions using 7.5Gy, 15Gy, and 30Gy with either null or Flagrp170 treatment,
displayed an improved curative therapeutic index of RT. We achieved tumor control and
improved survival with the lowest dose of RT with the addition of Flagrp170 as
compared to RT and null treatment (Figure 1E).

Flagrp170 Promotes Efficient Antigen Presentation Cell Priming and Activation in
Draining Lymph Nodes, 16-hours post-Vaccination.
SCC VII cells were cultured, irradiated, and infected with either null virus or Flagrp170
at a multiplication of infection (MOI) of 1:300 in vitro and used to vaccinate C3H/HeN
animals subcutaneously. Draining lymph nodes (DLNs) were then harvested after 16hours post vaccination and analyzed via flow cytometry (Figure 2A). Upon analysis,
CD11b+, CD11c+ dendritic cells in the animals’ DLNs, vaccinated with irradiated and
Flagrp170 infected SCC VII tumor cells, displayed a significant CD80, and CD86
receptor increases, as compared to null virus infected SCC VII group (Figure 2B).
Within the subsets of dendritic cells, CD8+ dendritic cells (Figure 2C) and CD103+
dendritic cells (Figure 2D) expressed a higher frequency and mean fluorescence
intensity (MFI) of both CD40 and MHC II after vaccination with Flagrp170 irradiated cells
at the DLN site. These data support the immunostimulatory function of Flagrp170 at the
level of the antigen presenting cells whose sentinel function is to initiate an adaptive
immune response to processed antigens.
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Radiation Therapy Combination Conferred Protection through Flagrp170,
Improves Survival and Tumor Re-occurrence Risk.
C3H/HeN female mice were inoculated with SCC VII tumor cells subcutaneously on
day-0. Once tumors reached 5-6mm of diameter in size, three 10Gy fractions of RT
were delivered stereotactically in three days. Concomitantly, intratumoral treatment with
either null or Flagrp170 was also delivered q.a.d. for five doses, and the animals’ tumor
volumes and survival were measured and recorded. Animals that remained tumor free
for two months were subsequently re-challenged on the contralateral site with SCC VII
cells and monitored for tumor reoccurrence as depicted in the experimental schematic
in (Figure 3A). Flagrp170 combination RT treatment resulted in 86.67% survival, as
compared to the 33.33% survival rate of the combination null and RT treatment. This
survival difference was statistically significant via a Log-rank test (p <0.001) (Figure
3B). Animals that remained tumor free for two months, were re-challenged with SCC VII
tumors on the contralateral flank and then monitored for tumor re-occurrence. A
representative image of animals re-challenged with SCC VII tumors on the contralateral
side (Figure 3C) shows the conferred immunological protection from Flagrp170. There
was with 23% (3/13) tumor reoccurrence in the Flagrp170 combination group, as
compared to 100% (5/5) tumor reoccurrence in null combination group (RR=.18; p=
0.003; CI 95%) as displayed in the table and graphs in (Figure 3D). Splenocytes from
re-challenged animals were stimulate with whole cell lysates from SCC VII tumor cells
for 96-hours and then analyzed via flow cytometry for intra-cellular cytokine production.
The ex vivo splenocyte assay showed increased CD8+ T-cell activation and expression
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of granulocyte-macrophage colony stimulating factor (Gm-CSF) and IFN-γ as seen in
the representative plots in (Figure 3E) and graphs (Figure 3F).

Mechanisms of Tumor Rejection in the SCC VII Model post-Flagrp170 Treatment
Flagrp170 and RT combination treated animals were treated with the same treatment
regimen schedule described in (Figure 3). Two weeks after ablation of the primary
tumor animals were treated with targeted immune depleting antibodies including CD4 +
T-cells, CD8+ T-cells, and the IgG control antibodies. Three days after the beginning of
the selective immune depletion, animals were re-challenged with SCC VII cells on the
contralateral side and monitored for tumor re-occurrence. Animals treated with IgG
antibodies served as the control for the experiment and did not develop tumors as
expected. Interestingly, animals depleted of CD8+ T-cells did not develop tumors,
indicating that CD8+ T-cells, which have canonically been associated with antitumor
immunological memory were dispensable for protection. Three out of the five animals
depleted of CD4+ T-cells developed tumors indicating that in this model, they played a
causal role in immunological protection and memory response Figure 4.

Potentiation of the Abscopal Effect with Flagrp170 Treatment and Radiation
Therapy Provides Improved Antitumor Immunity at Distant and Untreated Sites.
C3H/HeN mice had bilateral SCC VII-OVA tumors implanted on the right and left flank
on day 0. Treatment of the right tumor began once it reached 5-6mm in diameter with
30Gy of RT delivered stereotactically in three fractions, and either null or Flagrp170
intratumoral treatments for five doses q.a.d. (Figure 5A). The contralateral tumor on the
left side of the animals remained untreated from the stereotactic RT or intratumoral
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injections serving as a pseudo-distant and metastatic site for this portion of the study.
Primary treated tumors on the right side achieved a complete response from animals in
both RT groups by day 18, as compared to the control group. The Flagrp170 RT
combination animals’ contralateral and untreated tumors grew at a significantly reduced
volume when compared to the null RT combination group (Figure 5B). Upon immune
analysis of tumor infiltrating leukocytes in the contralateral tumor, an increase of CD4+
and CD8+ T-cell frequency was found within the distant and untreated tumor.
Furthermore, both CD4+ and CD8+ T-cells had increased IFN-γ production in the
Flagrp170 and RT combination group as compared to the null and RT combination
(Figure 5C). Myeloid cells in the contralateral site were also examined via flow
cytometry. Flagrp170 and RT combination reprogramed the tumor microenvironment by
decreasing monocytic myeloid derived suppressor (m-MDSC) cell frequency and
increasing IL-12p40+ expressing dendritic cells in the contralateral and untreated tumor
site (Figure 5D). Splenocytes from tumor bearing animals were stimulated ex vivo with
whole tumor cell lysates for 96-hours and analyzed via flow cytometry. Flagrp170 and
RT combination therapy displayed increased levels of IFN-γ from CD8+ T-cells as seen
in both the representative flow cytometry plots and graphs (Figure 5E). Whole tumor
tissue was collected ex vivo for RNA extraction and then cDNA was prepared and
analyzed for Th1 genes via qPCR. Flagrp170 and RT combination produced higher
relative expression of Tbet, granzyme B, and IFN-γ as compared to null and RT
combination at the gene level, correlating with the TIL flow cytometry analysis (Figure
5F).
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MOC II HNSCC metastatic model controlled via Flagrp170 mediated abscopal
effect
In Figure 6, we used another well-known HNSCC animal model called MOC II, which is
syngeneic for C57BL/6 mice. MOC II as opposed to the MOC I cell line, exhibits a more
aggressive and metastatic growth in vivo and is far less immunogenic as compared to
MOC I, given its significantly lower expression of MHC I (188). Animals had MOC II
tumors implanted subcutaneously and when the tumors reached a volume of 5-6 mm in
diameter, the following treatments began: stereotactic RT, 7.5Gy in three fractions and
intratumoral infusion therapy with either null of Flagrp170 (2x108 PFU/50µL) for five
doses q.a.d. Animals were monitored for tumor volume and the combination therapy of
RT and Flagrp170 provided better tumor control as compared to RT and null Figure 6A.
Tissues were collected, RNA was extracted, cDNA was made and qPCR of target
immune genes within the tumor were analyzed. In the MOC II tumors, increases of IFNγ, TNF-α, and IL-15 were found in the combination treatment of RT and Flagrp170 as
compared to RT and null combination treatment group (Figure 6B). To further
investigate this tumor models potential for control, we used a high fractionated dose of
30Gy, which was delivered in three fractions at MOC II luc/Tdt tumors. These animals
were then monitored for tumor growth via caliper measurement (Figure 6C), IVIS
imaging for in vivo tumor burden monitoring (Figure 6D).

Flagrp170s Control of the B16 Melanoma Lung Metastasis Model
C57/BL/6 mice had a primary B16 tumor implanted subcutaneously and then three days
later an intravenous injection of B16 tumor cells were delivered for the establishment of
lung metastasis as previously described (115). RT groups showed efficacy in controlling
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the primary tumor growth, however, combination RT and Flagrp170 verses RT and null
trended towards significance (Figure 7A). Animals were sacrificed at day 21 and lungs
were removed ex vivo for imaging, and upon gross observation, groups that received
RT of the primary tumor appeared to experience more lung metastatic growth (Figure
7B). Further analysis of the lung tissue was conducted by blinded counting of gross
observational nodules, and a clonogenic assay was conducted of single cell
suspensions created from the lung tissue (Figure 7C). The blinding count numbers
trended with an increase of counts or increased metastasis with groups that received
RT, including the RT and Flagrp170 combination groups. However, the clonogenic
assay showed that that viable lung tumor cells seeded in 6-well plates to be a sign of
lower tumor burden. This could be explained as a rapid tumor growth in vivo generated
by ectopic intravenous injection of live tumor cells honing to the lung, and our
therapeutic agent requiring the 5-7 days for immune activation. This delay in production
of cytotoxic response still likely resulted in death-pathways being activated within the
tumor cells and this event would not have been accounted for in gross blinding counting
of nodules. Further analysis of the tissues will be required for a more holistic
understanding of the immunological response conferred by Flagrp170 in this model.
Upon analysis of the tumor infiltrating leukocytes, an increase of CD4 and CD8 T-cells
expressing IFN-γ was detected via flow cytometry in the primary site from the Flagrp170
treated groups (Figure 8A). Interestingly, CD4 T-cells made more IFN-γ in the primary
site than the Flagrp170 mono therapy group as compared to the RT and Flagrp170
combination treatment group. However, the trend reversed in the CD8 T-cell analysis,
as the combination group produced marginally more IFN-γ than the mono therapy
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group. Tumor tissues were also taken for analysis of qPCR immune related gene
expression at the primary site (Figure 8B). Flagrp170 groups at the primary site
produced more IFN-γ, granzyme B, IL-10, PD-1, and PDL2, while FoxP3 showed subtle
trends with RT treatment groups. Interestingly, Flagrp170 monotherapy group did trend
with IFN-γ, and granzyme B increases, as compared to RT and null treatment, but the
combination of Flagrp170 and RT made significantly more only in IFN-γ. Inhibitory
signals like IL-10, PD-1, and PDL2 were also more prevalent in the Flagrp170 treatment
groups as compared to RT and null treatment. However, the combination of RT and
Flagrp170 exacerbated all of these inhibitory signals at the tumor site significantly (IL-10
trending, not statistically significant) while FoxP3 showed trending results as well. Upon
flow cytometry immune analysis of the metastatic site (lung), CD4 T-cells appeared to
promote greater IFN-γ expression in the Flagrp170 as compared to RT and null.
Interestingly, CD4 T-cells in the lung expressed more IFN-γ in the Flagrp170 and RT
combination group as compared to the monotherapy of Flagrp170. CD8 T-cells
displayed modest increases of IFN-γ, when comparing RT and null verses Flagrp170
monotherapy. The combination of Flagrp170 did produce almost 15% more IFN-γ in the
CD8 T-cells of the lung as compared to RT and null treatment, however, deeper
analysis of the functionality of these CD8 T-cells would need to be conducted to further
support this claim (Figure 9A). In order to gain a further understanding of the immune
modulation at the metastatic site, lung tissues were taken for qPCR analysis of immune
related genes (Figure 9B). Immune activating genes like IFN-γ and granzyme B were
increased in the lung with Flagrp170 treatment of the primary tumor, and more
significantly with the combination treatment of RT and Flagrp170. IFN-β increases
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trended with groups receiving RT at the primary site as compared to control and
Flagrp170 monotherapy groups. Interestingly the addition of Flagrp170 to RT seemed to
cause this IFN-β to trend down, possibly because of the multiple inhibitory signals
occurring within the metastatic site. Several inhibitory signals like IL-10, PD-1, PDL1,
PDL2, and FoxP3 were also analyzed at the metastatic site. Flagrp170 monotherapy
had a trending increase of these aforementioned inhibitory signals however, the
combination of RT and Flagrp170 significantly increased IL-10, PD-1, PDL1, PDL2, and
FoxP3 at the metastatic site as compared to the monotherapy of Flagrp170. These data
could explain why the blinded counts of the tumor trended to the conclusion of
increased tumor burden. Conversely, the increased cytotoxic activity from Flagrp170
and RT treatment groups seen via both flow cytometry and qPCR analysis could explain
the significant viability differences from the clonogenic assay seen in (Figure 7C).
These data could be an indication of limitations of ex vivo flow cytometry analysis,
meaning that the immune suppression while the tissues were intact was lost through ex
vivo activation of the single cell suspension of tumor infiltrating leukocytes. Furthermore,
these data suggest that the B16 melanoma have cytokine sinks (i.e. “pockets of
concentrated immune-suppressive cytokines within tissues”) created with the robust
immune activation produced by Flagrp170 at the distant site (i.e. the lung) and that low
dose cyclophosphamide or other cytokine sink depleting agents would likely benefit this
current disease setting.
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DISCUSSION
The Double-edged Sword of RT
Given that more than 50% of cancer patients will be treated with RT, and that abscopal
effects are considered a clinically rare phenomenon, a comprehensive immunological
understanding of how to increase the likelihood of a clinical abscopal effect is a
landmark the field has yet to achieve. RT is delivered with a curative intent, most often
seen in combination with chemotherapy, especially in inoperable locations for patients
harboring metastatic disease. While there are positive effects in irradiating a primary
tumor, the cell death mediated by mitotic catastrophe does not always confer a positive
effect on metastatic tumors (189). The overwhelming body of evidence shows that
suboptimum irradiation (i.e conventional fractionation) of a primary tumor, increases
growth of metastatic lesions in several carcinoma settings, the earliest reports include
HNSCC (190-196). The best rationale explaining the enhancement of metastatic growth
has been seen in bladder and non-small cell lung cancer. In these clinical studies, upon
the RT of primary tumors, an increase of circulating tumor cells (CTCs) in the blood
were discovered, contributing to the increased metastatic burden (191). The proposed
mechanism of how this increase of CTCs occur is that RT stimulates regeneration and
growth of the tumor vascular system. While many schools of thought exist on how the
tumor vasculature is improved, alternatively activated macrophages or M2 polarization
is likely the most understood prominent and contributing factor. M2 macrophages are
known to promote wound healing, vascular regenerative cytokines, and antiinflammatory functions, hindering the Th1 pro-inflammatory response required for
successful antitumor immunity (197-199). Other immunosuppressive mechanisms
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reported in preclinical metastatic melanoma studies include PD-1 agonism. This
phenomenon was reported to occur via exosome mediated PDL1 shuttling to metastatic
tumor sites in vivo (200). This information lends a partial explanation of the phenotype
seen in the Figures 7-9 given that RT seemed to promote increased tumor burden and
immune suppression in the lungs. The aforementioned findings provide a glimpse into
the abyss of scientific discoveries in the field of RT, which have yet to be uncovered.
Given the double-edged sword RT wields, clinical decisions on dosing and fractionation
are made complicated beyond both measures, and current comprehension. Disease
state specific RT regiments have shifted to hypofractionation, designed to ablate the RT
treated tumor, given the clinical consequences of residual tumor in the primary site.
Studies have shown that higher doses provide greater clinical protection due to
disruption of the tumor vasculature, cytokine expression, and mitotic catastrophe (25,
120, 155, 181, 182, 201, 202). This leaves clinicians with a delicate task of protecting
normal tissue, yet delivering enough energy to the tumor site for curative intent.
Experiments presented in this thesis are only a fraction of the work that went into
investigating the RT regimens with positive or manageable effects on metastatic tumor
burden. Anecdotal evidence from numerous in vivo experiments over the past five years
indicate that the degree of metastatic tumor burden may alter RT dosages required for
ablation of the primary treated site. This discovery was made when animals with
increased tumor burden (metastatic models bearing two simultaneous tumors) required
higher doses of RT at the primary tumor for ablation, as compared to the RT doses in
animals harboring only a primary tumor (single tumor model). Additionally, a factor that
further increases the complexity includes the likely variance in sensitivity to RT
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mediated death of different cancer disease states. Given this knowledge, additional
molecular diagnostic tools or biomarkers could aid in the guidance of personalized RT
doses in given disease states. One example was an endonuclease called TREX1,
which was only produced at lower RT doses and was found to dampen the RT cGASSTING mediated immune response. This occurred via degradation of cytosolic DNA by
this endonuclease. In this study, hypofractionation led to improved immune responses,
and correlated with decreased expression of the endonuclease TREX1, responsible for
the loss of the cGAS-STING activation (17, 153). Logical next steps would be to validate
this phenomenon in various cancer disease states, as it has potential to be used as a
guiding clinical diagnostic tool for strategic delivery of RT. Altogether, RT has an infinite
potential for the management of this disease state, however, methods for personalized
RT dosing for the rare abscopal responses are yet to be elucidated in the clinic.

Immunological Conferred Abscopal Response and Protection via Flagrp170 and
RT Combination Treatment
The collective data shown in this thesis indicates that Flagrp170 intratumoral treatments
pair synergistically with RT. This was achieved by activating the immune response, at
distant and untreated metastatic sites in both HNSCC and melanoma. While
discernable and significant tumor control was observed in the HNSCC models, the B16
metastatic melanoma model demonstrated questionable efficacy in tumor control with
the addition of RT. Interestingly, in the SCC VII HNSCC model, we showed that
previously cured animals with RT and Flagrp170 displayed a loss of immunological
protection after being rechallenged with live tumor cells if CD4 T-cells were neutralized
using antibody depletion. This finding is contrary to canonical school of thought in T-cell
49

tumor immunology, given that direct killing and cytotoxic effects are generalized with the
activity and function of CD8 T-cells. Nonetheless, there is a growing body of evidence
that shows that CD4 T-cells also direct cytotoxic killing via MHC II in melanoma
preclinical and clinical ICB studies alike (203). In one study, animals bearing MMTVPyMT breast cancer tumors were treated with combination immunotherapy, then T-cells
were sorted from peripheral tissues after treatment were infused into naive untreated
animals bearing MMTV-PyMT tumors. The results of this experiment showed a strong
dependence on CD4 T-cells maintaining tumor control as compared to CD8 T-cells.
Furthermore, a phenotype of CD4+ CD44+ CD62L- CD69+ CD27lo Tbet+ T-cells were
determined to be the specific subset responsible for the immunological protection
conferred from the adoptive transfer. The group in this publication provided further
evidence in elucidating this novel CD4+ T-cell subset by studying patients with
advanced staged melanoma, treated with anti CTLA-4 and Gm-CSF. They found that
patients who were responders to this treatment regimen expressed a high frequency of
this CD4+ T-cell subset in peripheral blood, re-confirming this subsets importance in the
field (204). Additionally, Flagrp170 is a danger signaling chimeric heat shock protein
vaccine, that is capable of delivering whole tumor specific or associated proteins to
APCs. This biological activity allows for a larger variety of epitopes of a given antigen to
be displayed by the APC, not only by cross presentation on MHC I activating CD8 Tcells, but also, conventional peptide presentation on MHC II as shown in this thesis
(Figure 2). This indicates that CD4 T-cells may also play a sentinel role in reinvigorating
the canonically assumed protective effector or memory effector functions of CD8 T-cells
upon rechallenging with live tumor cells. This idea is evidenced in the literature from
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reports showing that tumors with a scarcity of cross presenting DCs aid the CD4 T-cell
response. This is due to the abundance of MHC II peptide expression, and the known
increased MHC II peptide binding promiscuity as compared to MHC I (205).
Furthermore, a study showed that long peptide vaccine-based immunotherapy in the
melanoma setting also showed that CD4 T-cell activation was responsible for an
efficient cytotoxic CD8 T- cell response in tumor rechallenge settings (206). Given
Flagrp170’s mechanism of action, it is scientifically possible for anyone of these
aforementioned scenarios to be the rationale for our experimental observations.

Flagrp170s Potential for Clinical Translation and Efficacy in HNSCC and Future
Directions
This therapy is well situated in the field given the dire need for an immune potentiating
agent capable of vaccinating patients, and generating pre-existing immunity given the
prevalence of ICB implementation in the clinic. The Grp170 backbone is well reported
to deliver whole proteins and therefore could provide the most diverse repertoire of
peptide antigens of any given TAA or TSA. This will increase the probability of an MHC I
or MHC II peptide binding of cognate CD8 or CD4 T-cells. This in turn can benefit a
wide variety of patients considering the vast heterozygosity of the HLA classes between
patients, and the antigenic determinant effects caused by those differences. This means
this therapy will serve as an off-the-shelf immunotherapeutic agent, which can provide
personalized vaccination to the current antigens being expressed by patient’s tumors.
This concept further analyzed, also means that if there is a loss of antigenicity, or
patients become refractory after treatment, additional vaccinations may reorient the
immune response to the new antigen targets expressed by the tumor. The data
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presented in this thesis supports its implementation in the HNSCC RT setting, as it may
reduce the required dose to achieve tumor volume control and long-term immunological
memory. In particular, standard clinical RT regiments in HNSCC are within the range
used in several of the HNSCC experiments presented, therefore its application in the
neo-adjuvant therapy setting should be perused. Furthermore, our agent may aid in
exploiting the therapeutic index of RT, achieving cures with lower doses and improving
quality of life after treatment. Flagrp170’s potential in the HNSCC setting still requires
further research. However, these data suggest its implementation in the clinic could lead
to improvement of ICB response rates, reprograming of the tumor microenvironment,
and increased abscopal effects resulting in higher cure rates and improved quality of life
metrics for cancer patients.
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Figure 1. Flagrp170 potentates the danger signals from radiation therapy
(RT), synergizing to promote anti-tumor immunity.
Single tumor model (SCC VII) combination of RT with Flagrp170 synergies for
tumor control. Animals were treated once tumors reached 7-8mm in diameter with
three fractions radiation therapy (RT) 2.5Gy consecutively and intra-tumoral
injections of empty viral vector (CMV) or Flagrp170 for five doses q.a.d. (Figure
1A) TIL analysis of CD8 T-cells at the tumor site (flow cytometry). (Figure 2B). TIL
analysis of CD4 T-cells at the tumor site. (Figure 1C) Whole cell lysate (WCL) or
OVA protein stimulation of splenocytes from SCC VII-OVA tumor bearing animals
stimulated for 96-hours. (Figure 1D) Quantitative qPCR of immune related genes
from SCC VII treated tumor tissue. (Figure 1E) RT dose response using 7.5Gy,
15Gy, 30Gy total amounts delivered within three fractions, with either null virus or
Flagrp170 for five doses q.a.d. (Figure 1F) Experiments representative of three or
more independent experiments. Two-way ANOVA analysis was conducted with
GraphPad Prism. Asterisks denotes statistical significance of: * P≤ 0.05, **
P≤0.01, *** P≤0.001, **** P≤0.0001
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Figure 2. Flagrp170 promotes efficient APC priming and activation in draining
lymph nodes 16hrs post-vaccination.
Figure describing vaccination model and draining lymph node harvesting 16 post-vaccination in
+
+
figure 2B, 2C, 2D. (Figure 2A) CD11b CD11c conventional DCs receptor expression of
+
CD80 and CD86 after vaccination (Figure 2B). CD8 DCs analysis (flow cytometry) (Figure
+
2C) CD103 DC analysis (flow cytometry) (Figure 2D) Experiments representative of three or
more independent experiments. Students T-test analysis was conducted with GraphPad Prism.
Asterisks denotes statistical significance of: * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001
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C.

D.
Summary
Table
Tumor Free
survival
(TFS) 2
Months
(N=15)
% TFS
RT+ Null

LogRank Rechallenged
Tumor
Test
Animals Reoccurrence RR p value

5/15

33.33%

13/15

p
86.67% <0.001

RT + Flagrp170

-

RT (n=5)
RT+
Flagrp170
(n=13)
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Figure 3. Radiation Alone and the Combination Treatment of Radiation and
Flagrp170 Group Provided Protection in Established (5-6mm) SCC VII Tumors.
Animals received no treatment (Control), or were treated with 30Gy of RT delivered
in three fractions with a combined with empty viral vector (Null), or RT+Flagrp170 for
five doses q.a.d. once tumors reached 5-6mm in diameter (Figure 3A). The
RT+Flagrp170 treatment group provided improved tumor free for over four months
as compared to RT+ Null group (Figure 3B). Animals that remained tumor free for
two to four months after their treatment regimen were then rechallenged on the
5
contralateral side (left) with 2x10 cells/animal. RT+ Null group (n=5/15) survival was
less than that of the RT+Flagrp170 (n=13/15) and a representative image is shown
in (Figure 3C) A summary table with statistical analysis of tumor free survival after
treatment using a Log-Rank Test and the relative risk (RR) of tumor reoccurrence
after being rechallenged with live tumor cells is depicted in (Figure 3D) Animals
rechallenged with SCC VII tumors had splenocytes harvested and stimulated ex-vivo
with SCC VII whole cell lysates and then analyzed via flow cytometry.
Representative samples show in (Figure 3E) and graphical representation of CD8 Tcell analysis in (Figure 3F). Experiments representative of three or more
independent experiments. Two-way ANOVA, Log rank, and relative risk analysis was
conducted with GraphPad Prism. Asterisks denotes statistical significance of: * P≤
0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001
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A.

Figure 4. Head and neck tumor cells infected with Ad. Flagrp170 promotes
immunity to tumor challenges via CD4 effector function.
Immune antibody depletion of previously cured SCC VII and rechallenged tumor bearing
+
animals showed that CD4 T-cells were required for protection (Figure 4A)
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Figure 5. SCC VII Contralateral tumor Model: Combination treatment of Flagrp170
and RT therapy provides improved antitumor immunity at distant and metastatic
sites.
5

Animals had SCC VII tumors implanted in both flanks on day0 (2x10 cells/right flank;
5
1x10 cells/left flank) and were treated with adenoviral intertumoral treatments of empty
viral vector (CMV) or Flagrp170 for five doses q.a.d. once tumors reached 5-6mm.
Radiation therapy was also delivered with on the first day of viral treatments with three
fractions of 10 Gys on days 5,6, and 7. (Figure 5A) Primary and contralateral tumor
growth curve of SCC VII tumor model. (Figure 5B) Flow cytometry of TILs in the
contralateral tumor. (Figure 5C) TIL analysis of myeloid derived suppressor cells CD11b+
gating for analysis of Ly6C and Ly6G. (Figure 5D) Splenocyte whole tumor cell lysate
activation assay of tumor bearing animals. (Figure 5E) Analysis of immune related genes
of at the contralateral tumor site. (Figure 5F) Experiments representative of three or more
independent experiments. Two-way ANOVA analysis was conducted with GraphPad
Prism. Asterisks denotes statistical significance of: * P≤ 0.05, ** P≤0.01, *** P≤0.001, ****
P≤0.0001
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Figure 6. Combination treatment of Flagrp170 and RT therapy provides
improved anti-tumor immunity against a naturally metastatic HNSCC model.
Animals had MOC II cells implanted subcutaneously on Day 0. Intertumoral
treatments of empty viral vector (null) or Flagrp170 for five doses q.a.d. began
once the primary tumors reached 5-6mm. Radiation therapy was also delivered
with on the first day of viral treatments with three fractions of 2.5Gys on days 5,6,
and 7. (Figure 6A) Analysis of immune related genes via qPCR from MOC II
treated tumors (Figure 6B) Primary tumor growth curve of MOC II-Luc tumor
model treated with higher dose RT, (10Gy x3) for long term analysis of survival.
(Figure 6C) Tumor growth monitored via luciferase activity in vivo using an IVIS
(Figure 6D) Experiments representative of two or more independent experiments.
Two-way ANOVA analysis was conducted with GraphPad Prism. Asterisks
denotes statistical significance of: * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001
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Figure 7. B16 Melanoma Primary and Lung Metastatic Model
5

C57/B6 mice were subcutaneously injected with B16 (2x10 cells/animal) for a primary
5
tumor on day 0, then had an intravenous injection of B16 (1x10 per/animal) cells on day 3.
Animals received treatment once the primary tumor reached 5-6mm with radiation 30Gys
8
fractionated into three doses, and five doses of Flagrp170 2x10 PFU/animal delivered
q.a.d. (Figure 7A) Representative ex vivo gross observational image of lungs from tumor
bearing mice. (Figure 7B) Lung nodules of B16 colonies were counted in a blinded fashion
and then lungs were digested and a single cell suspension was prepared for TIL isolation
4
and seeding for a clonogenic assay (1x10 cells/well). (Figure 7C) Two-way ANOVA
analysis was conducted with GraphPad Prism. Asterisks denotes statistical significance of:
* P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001
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Figure 8. Combination Therapy Induces Increased T-cell Activation
Concomitantly with Strong Inhibitory Signals at the Tumor Site.
+

+

TIL analysis of CD4 and CD8 T-cell IFN-γ production from the primary tumor. (Figure
8A) Tumor tissue was obtained from the primary (treated) tumor and analyzed via
qPCR for expression of various immunological genes. IFN-γ increased in the
combination group while granzyme B expression decreased and IL-10, PD-1, and
PDL2 all increased with the combination group. (Figure 8B)
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Figure 9. Metastatic Site Experienced Increased Immune Stimulation and while
Undergoing Robust Inhibitory Signals.
+

+

TIL analysis of CD4 and CD8 T-cell IFN-γ production from the metastatic tumor site
(lung). (Figure 9A) Lung tissue was harvested from animals and used for qPCR
analysis of gene expression at the tissue level. IFN-γ and granzyme B expression were
increased in the combination treatment groups indicating a strong inflammatory
response. IFN-Β induction seemed to be driven by groups that included RT as a
treatment modality. Inhibitory markers (PD-1, PDL1, PDL2), tolerogenic transcription
factors (FoxP3), and soluble factors like IL-10 were most present in the combination
treatment group (RT+ Flagrp170). (Figure 9B)
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